NGEN stock Statistics — Nervgen Pharma CORP. filings, insiders & smart money

Price chart (1D to 10Y)

Licensed market data — shown to members, not published to the open web.

Beta: Sign in
Shares outstandingAs of 2025-12-31 · filed common shares: 79.64M
Shares float: Sign in
Float %: Sign in
Insider ownership: —
Institutional ownership: Sign in
Short interestShare of shares outstanding, at settlement: 6.83%
Short ratioDays to cover, as published by FINRA: 8.29
Short volume (5D)Share of FINRA reporting-facility volume sold short, daily flow: 55.80%
Short volume (20D)Share of FINRA reporting-facility volume sold short, daily flow: 60.90%
Avg volume (10D)

Source: SEC filings. Information and analytics, not investment advice.

Sign in

Avg volume (3 months)

Gross margin: —
Operating margin: —
Net margin: —
EBITDA margin: —
Return on equityNet income (FY Dec 25) ÷ average shareholders equity: -726.87%
Return on assetsNet income (FY Dec 25) ÷ average total assets: -207.11%

Cash & equivalentsas of Dec 25: CAD 22.06M
Total cash: Sign in
Total debtBorrowings + finance and operating lease liabilities, as of Dec 25: CAD 8.36K
Debt / equityas of Dec 25: 0.14%
Current ratioas of Dec 25: 1.32
Quick ratio(Cash + marketable securities + receivables) ÷ current liabilities, as of Dec 25: 1.28
Operating cash flowFY Dec 25: -CAD 19.49M
Free cash flowUnadjusted FCF = CFO − capex · FY Dec 25: -CAD 19.49M
TTM revenue / diluted share: —